PANGAEA Oncology S.A.

Industry / private company


Location: Barcelona, Spain (ES) ES

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (2026) Schmid P, Cortes J, Dent RA, McArthur HL, Pusztai L, Kuemmel S, Denkert C, et al. Journal article ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (2026) Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, et al. Journal article TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10 (2026) Rugo HS, Schmid P, Cortes J, Takano T, Fasching P, Park YH, Bianchini G, et al. Journal article Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (2026) Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, et al. Journal article